Dolutegravir-Lamivudine Tablets are a fixed-dose combination used in the treatment of human immunodeficiency virus, commonly known as HIV. This combination contains two antiretroviral medicines, dolutegravir and lamivudine, which work together to reduce the amount of virus in the body and strengthen the immune system. It is usually taken once daily and is often used as a complete regimen for people living with HIV, especially those who are beginning treatment or switching from another combination.

Mechanism of Action

Both dolutegravir and lamivudine act on different stages of the HIV replication cycle:

• Dolutegravir is an integrase strand transfer inhibitor. It blocks the HIV enzyme called integrase, which is needed for the virus to insert its genetic material into human DNA. This prevents the virus from multiplying inside the body’s cells.

• Lamivudine is a nucleoside reverse transcriptase inhibitor. It blocks the reverse transcriptase enzyme, which the virus needs to make copies of its genetic material. This stops the virus from replicating.

  Uses

  Dolutegravir-Lamivudine Tablets are used for:

  • Treatment of HIV infection in adults and adolescents

  • Providing a simplified treatment option as a two-drug regimen for those with suppressed viral loads

  • Improving quality of life by reducing pill burden and maintaining long-term viral control

    Adverse Effects

    Most people tolerate this combination well, but some may experience side effects such as:

    • Headache or tiredness

    • Trouble sleeping or vivid dreams

    • Nausea or upset stomach

    • Increase in liver enzymes in some individuals

    • Mild weight gain in some cases

    • Rare allergic reactions or mood changes